Frédéric Oudéa, on November 28, 2017, in Fontenay-sous-Bois. CHARLES PLATIAU / REUTERS Frédéric Oudéa, current CEO of Société Générale, will be proposed as the next non-executive chairman of the board of directors of Sanofi, the pharmaceutical group announced on Monday, September 5 in a press release. Sanofi specifies that Mr. Oudéa was appointed censor on September 2 by the group’s board of directors, and that his appointment as director will be proposed at the next general meeting of shareholders. Read also: Article reserved for our subscribers At Société Générale, battle in sight for the succession of Frédéric Oudéa Departure from Société Générale in 2023 Following this general meeting – the precise date of which has not yet been set, but which is usually held in the spring -, “it will be proposed to the Sanofi Board of Directors the appointment of Frédéric Oudéa as non-executive chairman of this board, replacing Serge Weinberg whose term of office will have expired”. “Frédéric Oudéa announced that he would leave his position as CEO and director of Société Générale in May 2023”, at the end of his current mandate, recalls Sanofi. Read also Article reserved for our subscribers Sanofi boosted by the success of its flagship drug, Dupixent “Frédéric Oudéa and Paul Hudson, CEO of Sanofi, will form an excellent duo to position Sanofi as a modern healthcare company and strengthen its leadership position French, European and global at the service of patients”, for his part commented Serge Weinberg, quoted in the press release. “I am very happy to join Sanofi’s Board of Directors as a non-voting member, with, subject to the agreement of its shareholders, the prospect of taking over as Chairman. I am extremely motivated by the prospect of contributing in the coming years to the strategy and sustainable development of Sanofi, a leading company in a strategic health sector, with high impact and in full transformation, and to be the guarantor of quality governance of the group,” said Mr. Oudéa. Read also: Article reserved for our Dépakine subscribers: Sanofi’s responsibility recognized by the courts Le Monde with AFP